(Bloomberg) -- Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. filed to list its shares in Hong Kong, adding to the growing number of publicly traded mainland Chinese firms looking to have their stock trade in the financial hub.
Chinese companies whose shares already trade in the mainland are betting that adding a Hong Kong listing would make it easier for foreign funds to invest in them. Hengrui’s share sale could fetch at least $2 billion, people familiar with the situation have said.
Morgan Stanley, Citigroup Inc. and Huatai Securities Co. are arranging the deal.
©2025 Bloomberg L.P.